The following is a summary of “Karyotype evolution of myelodysplastic syndrome and acute myeloid leukemia with TP53 mutations,” published in the February 2025 issue of the International Journal of ...
Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety ...
In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.
The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...
Medical Xpress on MSN10d
Why is there an increase in lung cancer among women who have never smoked?Lung cancer cases are increasing in people who have never smoked, especially in women, a new study by the World Health ...
Aptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollment continues across U.S. sites.
Hosted on MSN24d
The TP53 Gene and Its Role in CancerThe TP53 gene is a gene that is mutated in many cancers. It is the most common gene mutation found in cancer cells. A tumor-suppressor gene, TP53 codes for a protein that inhibits the development ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
Interestingly, genetic analysis indicated that the patient who achieved complete response had MYC amplification and TP53 mutations, suggesting that CDK9 inhibition with SLS009 may overcome drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback